For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Op-Eds
Reform Obamacare, Don’t Just Extend It
Obamacare must be reformed, not just extended, as the House recently voted to do. Intended as a program to help people gain insurance coverage, it…
Freedom Works Radio
Jeremy Nighohossian, Competitive Enterprise Institute “Trump Healthcare Plan a Mixed Bag”: Freedom Works Radio Show
Freedom Works Radio show interviews CEI’s expert on healthcare Listen to Freedom Works Radio…
NewsTalkSTL
NewsTalkSTL: Jeremy Nighohossian of Competitive Enterprise Institute 1-19-2026
Search Posts
Op-Eds
Often Wrong, Never in Doubt
Times have changed. Two years ago, tennis great Novak Djokovic could not play in the U.S. Open tournament. It was not because he had Covid-19…
Blog
Can AI thrive in health care’s HIPAA-shaped box?
Innovation continues to transform health care, enabling us to live longer and healthier lives. And now artificial intelligence (AI) is poised to supercharge that…
The Wall Street Journal
The FTC Goes Evidence-Free
Through three years of Lina Khan’s leadership, the Federal Trade Commission has suffered an unprecedented streak of high-profile court defeats. That’s because the agency regularly makes…
Blog
This week in ridiculous regulations: Blood donors and paper marketing
Donald Trump survived an assassination attempt. The Republicans held their convention in Milwaukee. Sen. Robert Menendez (D-NJ) was convicted on bribery charges and resigned, leaving…
Blog
Missing the economists in FTC’s latest PBM study
The Federal Trade Commission (FTC) released its not-so-objectively titled interim report on Pharmacy Benefit Managers (PBMs): Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa Holyoak…